Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12506948 | 0.86 | CDC7 (0.51) | NPC1RAB9AROCK1ROCK2RPS6KB1 | |
| SCHEMBL8174211 | 0.82 | ROCK1 (0.44) | KDRPIK3CAROCK1ROCK2RPS6KB1 | |
| SCHEMBL1229709 | 0.82 | ROCK1 (0.58) | KDRNPC1RAB9ASYKTNIK | |
| SCHEMBL2257092 | 0.80 | RPS6KB1 (0.40) | ROCK1ROCK2RPS6KB1 | |
| SCHEMBL2257284 | 0.78 | NPC1 (0.53) | KDRNPC1RAB9ASYKPIK3CA | |
| Hydrochloric Acid SCHEMBL2255980 | 0.78 | NPC1 (0.52) | KDRNPC1RAB9ASYKPIK3CA | |
| SCHEMBL12507117 | 0.76 | RPS6KB1 (0.41) | ROCK1ROCK2RPS6KB1 | |
| SCHEMBL12506921 | 0.75 | ROCK2 (0.41) | ROCK1ROCK2RPS6KB1 | |
| SCHEMBL12507240 | 0.75 | RPS6KB1 (0.44) | ROCK1ROCK2RPS6KB1 | |
| SCHEMBL12507123 | 0.75 | ROCK2 (0.42) | ROCK1ROCK2RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155728-B1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | claimed |
| EP-2155728-B1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| EP-2155728-B1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-8334309-B2 | Heterocyclic indazole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110190355-A1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-04 | — | — | US | disclosed |
| WO-2008138448-A2 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190355-A1 | HETEROCYCLIC INDAZOLE DERIVATIVES | SGK3, SGK2, SGK1 | KDR 2547/4885NPC1 2851/4885RAB9A 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.